—神経疾患患者に対するワクチンと副反応（1）—総論

COVID-19 Vaccines for Patients with Neurological Diseases

神経疾患患者の多くが高齢者で基礎疾患を有している。そのためCOVID-19罹患時には重症化のリスクが高まると考えられ，基本的にワクチン接種が推奨される。副反応にはアナフィラキシーのように重篤なものもあるが，他の副反応を含め頻度は稀なことが多く，COVID-19重症化リスクを踏まえてワクチン接種を考慮する必要がある。ワクチンによる感染と重症化の予防効果は経時的に減衰するため，長期化に備えてブースター接種を検討する必要がある。

Abstract

As most patients with neurological diseases are older adults and have underlying diseases, they are at high risk for adverse outcomes with coronavirus disease 2019 (COVID-19). Therefore, COVID-19 vaccination is strongly recommended for such patients. Anaphylaxis is a serious adverse reaction to vaccines, but its frequency is rare, and other adverse events are transient. We must consider the need for COVID-19 vaccines in consideration of the severity risk of COVID-19. As the effectiveness of some vaccines has been shown to wane after 4-6 months, we must consider the administration of a third vaccine as a booster.